TRIB3 Promotes Multiple Myeloma Progression by Stabilizing SSRP1 via USP10-Mediated Deubiquitination Academic Background Multiple Myeloma (MM) is the second most common hematologic malignancy globally, characterized by aggressive progression, frequent relapse, and resistance to therapy. Although current multi-drug combination therapies have signifi...

The Impact of Soluble B-Cell Maturation Antigen (sBCMA) on Multiple Myeloma Therapy: Interpreting the Latest Research Findings In recent years, cell-based immunotherapies have demonstrated enormous promise in the treatment of multiple myeloma (MM). Among these, BCMA-targeting T-cell engagers (TCEs) and chimeric antigen receptor (CAR) T-cell therapi...

Interpretation of Research on the Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma Following Anti-BCMA Therapies Academic Background Multiple myeloma (MM) is a malignancy stemming from plasma cells within the bone marrow. Recent advancements in treatment have significantly improved overall survival rates. How...

Precision Medicine | Quantitative Comprehensive Survival Prediction for Patients with Multiple Myeloma: Based on Bortezomib Induction Therapy, High-Dose Treatment, and Autologous Stem Cell Transplantation Introduction Multiple myeloma is a malignant hematological disease characterized by the accumulation of clonal plasma cells within the bone marro...